BRPI9608799B8 - análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. - Google Patents

análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. Download PDF

Info

Publication number
BRPI9608799B8
BRPI9608799B8 BRPI9608799A BRPI9608799A BRPI9608799B8 BR PI9608799 B8 BRPI9608799 B8 BR PI9608799B8 BR PI9608799 A BRPI9608799 A BR PI9608799A BR PI9608799 A BRPI9608799 A BR PI9608799A BR PI9608799 B8 BRPI9608799 B8 BR PI9608799B8
Authority
BR
Brazil
Prior art keywords
pro
grf
fatty body
increased biological
pharmaceutical formulation
Prior art date
Application number
BRPI9608799A
Other languages
English (en)
Inventor
Ibea Michel
Brazeau Paul
Abribat Thierry
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9608799(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BRPI9608799B8 publication Critical patent/BRPI9608799B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)

Abstract

"análogo pro-grf - corpo graxo quimérico com aumentada potência biológica, formulação farmacêutica, e, processos para o aumento do nível de hormônio de crescimento, para o diagnóstico de deficiências de hormônio de crescimento, para o tratamento de retardo do crescimento ou ananismo pituitário, de ferida ou cicatrização de ossos e de osteoporose em um paciente, e, para melhoria do anabolismo de proteína em humanos ou animais". a presente invenção refere-se a análogos de pro-grf corpo-graxo quiméricos com aumentada potência biológica, sua aplicação como agentes anabólicos e no diagnóstico e tratamento de deficiências de hormônio de crescimento. os análogos pro-grf -corpo graxo quiméricos incluem uma porção hidrófoba (cauda) e podem ser preparados, ou por ancoragem de uma ou várias caudas hidrófobas ao grf, ou por substituição de um ou vários aminoácidos por um resíduo pseudomicelar na síntese química de grf. os análogos de grf da presente invenção são biodegradáveis, não imunogênicos e demonstram uma melhorada potência anabólica com uma dosagem reduzida e atividade prolongada.
BRPI9608799A 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. BRPI9608799B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
BRPI9608799B8 true BRPI9608799B8 (pt) 2019-11-05

Family

ID=27036979

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9608799-4A BR9608799B1 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
BRPI9608799A BRPI9608799B8 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI9608799-4A BR9608799B1 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Country Status (13)

Country Link
US (2) US5861379A (pt)
EP (1) EP0828758B1 (pt)
JP (1) JP3576170B2 (pt)
KR (1) KR100543190B1 (pt)
AT (1) ATE204881T1 (pt)
AU (1) AU697119B2 (pt)
BR (2) BR9608799B1 (pt)
CA (1) CA2222068C (pt)
DE (1) DE69614849T2 (pt)
DK (1) DK0828758T3 (pt)
ES (1) ES2163020T3 (pt)
PT (1) PT828758E (pt)
WO (1) WO1996037514A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
CA2303702A1 (en) * 1999-04-12 2000-10-12 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
AU2004281084B2 (en) * 2003-10-20 2010-08-12 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012037519A2 (en) * 2010-09-16 2012-03-22 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
CN103547591A (zh) 2011-04-21 2014-01-29 瑟瑞技术公司 生长激素释放因子(grf)类似物及其用途
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US8871713B2 (en) 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109153712B (zh) 2016-04-19 2022-09-16 格里芬制药国际公司 Peg化生物活性肽及其用途
WO2024091863A1 (en) * 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
KR100543190B1 (ko) 2006-06-23
CA2222068C (en) 2007-04-10
AU5683396A (en) 1996-12-11
DK0828758T3 (da) 2002-01-07
DE69614849D1 (de) 2001-10-04
JP3576170B2 (ja) 2004-10-13
PT828758E (pt) 2002-02-28
KR19990021938A (ko) 1999-03-25
EP0828758B1 (en) 2001-08-29
EP0828758A1 (en) 1998-03-18
DE69614849T2 (de) 2002-05-16
MX9709098A (es) 1998-06-30
AU697119B2 (en) 1998-09-24
JPH11505807A (ja) 1999-05-25
BR9608799B1 (pt) 2009-12-01
US5861379A (en) 1999-01-19
WO1996037514A1 (en) 1996-11-28
ATE204881T1 (de) 2001-09-15
BR9608799A (pt) 1999-12-07
ES2163020T3 (es) 2002-01-16
US5939386A (en) 1999-08-17
CA2222068A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
BR9608799B1 (pt) análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
ATE204467T1 (de) Orale darreichungsform
Erspamer et al. Pharmacological actions of caerulein
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
DK193887D0 (da) Fysiologisk aktivt peptid
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
HK16492A (en) Pharmaceutical compositions of somatostatin analogues
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
GR3005612T3 (pt)
GB1395090A (en) Stabilized hormone compositions
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
US3670079A (en) Anabolic agents
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
IL85029A (en) Microcrystalline cis diammineplatinum(ii)complex of 1,1-cyclobutanedicarboxylic acid,its preparation and cytostatic pharmaceutical compositions containing it
CA2073554A1 (en) Water-soluble composition for sustained-release
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
Vinson et al. α-MSH analogues and adrenal zona glomerulosa function